Belkin Vision announced that it has received €17.5M of blended financing in grants and equity from the European Innovation Council Accelerator (EIC). Belkin Vision’s glaucoma laser is currently in the final stages of clinical trials across the UK and Europe, and if approved, would be the first and only contactless laser treatment for glaucoma, according to a company news release.
OKYO Pharma, of London, announced Dec. 13 that its first drug candidate, OK-101, developed to treat dry eye disease as an anti-inflammatory, also showed potent ocular pain reducing properties in a mouse model. OK-101 is a novel, long-acting G protein-coupled receptor-based lipidated chemerin peptide developed to bind to ChemR23 receptors in the eye and interrupt the inflammatory response.
French company Nicox announced Dec. 9 that it had raised €15 million (US $16.9 million) through a private placement of 6 million new ordinary shares. Warrants issued in the private placement could provide an additional €16.4 million (US $18.5 million) in gross proceeds if they were to be fully exercised, Nicox said.
Ocugen announced Dec. 9 that the US FDA had accepted the company’s investigational new drug (IND) application to initiate a first-in-human Phase I/II trial of its gene therapy candidate for retinitis pigmentosa (RP).
Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuing its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery.
Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients …
GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared to unilateral injection.
Rayner Surgical Group (‘Rayner’) and Omeros Corporation (‘Omeros’) are delighted to announce the transfer of Omeros’ ophthalmology assets, including OmidriaTM, to Rayner. This will enable the creation of a significant commercial, regulatory and marketing infrastructure in the US, with a broad range of products, including intraocular lenses (IOLs), for cataract surgeons. OmidriaTM has excellent and substantial clinical data supporting the maintenance …